Publication:
Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Simple item page
dc.contributor.authorBolanos, Rafael
dc.contributor.authorAraos Bralic, Rafael Ignacio
dc.contributor.authorGonzalez, Cecilia
dc.contributor.authorSepulveda, Dino
dc.contributor.authorFalconi, Juan
dc.contributor.authorAverin, Ahuva
dc.contributor.authorAtwood, Mark
dc.contributor.authorQuinn, Erin
dc.contributor.authorLaw, Amy
dc.contributor.authorMendes, Diana
dc.date.accessioned2026-09-02T20:53:57Z
dc.date.available2026-09-02T20:53:57Z
dc.date.issued2025
dc.description.abstractBackground: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk. Research design and methods: A cohort model was developed to evaluate cost-effectiveness of strategies preventing RSV-LRTI in infants. Using the model, we calculated the economically justifiable price (EJP) of maternal RSVpreF vaccination (MV) versus no intervention and then evaluated the cost-effectiveness of MV (cost/dose assumed at EJP) with complementary use of monoclonal antibody nirsevimab for unprotected infants (MV+N) versus nirsevimab alone (NA) to prevent RSV-LRTI. Nirsevimab published price was $260.00; costs/prices reported in 2023 US$. Results: NA yielded 20,247 cases (hospital: 3,773, emergency ward: 16,474) and $57.2 million (M) in total costs (medical: $6.3 M, intervention: $48.7 M, indirect: $2.2 M). MV+N yielded 23,906 cases (hospital: 3,137, emergency ward: 20,769) and $28.7 M in costs (medical: $4.8 M, intervention: $21.7 M [RSVpreF assumed $75.77/dose; nirsevimab procured $260.00/dose], indirect: $2.2 M). With costs lower by $28.4 M and increased quality-adjusted life-years, MV+N would be cost-saving versus NA. Conclusions: RSVpreF vaccination among pregnant women along with nirsevimab for unprotected infants in Chile would be the most efficient use of resources, yielding substantial cost savings compared to use of nirsevimab alone. Trial registration: ClinicalTrials.gov NCT04424316 NCT03979313.
dc.description.versionVersión Publicada
dc.identifier.citationBolanos R, Araos R, Gonzalez C, Sepulveda D, Falconi JF, Averin A, Atwood M, Quinn E, Law AW, Mendes D. Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus. Expert Rev Vaccines. 2025 Dec;24(1):904-913. doi: 10.1080/14760584.2025.2562201
dc.identifier.doihttps://doi.org/10.1080/14760584.2025.2562201
dc.identifier.urihttps://hdl.handle.net/11447/11056
dc.language.isoen
dc.subjectChile
dc.subjectRespiratory syncytial viruses
dc.subjectCost-effectiveness analysis
dc.subjectInfants
dc.subjectMonoclonal antibodies
dc.subjectVaccine
dc.titleCost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceExpert review of vaccines
dspace.entity.typePublication
relation.isAuthorOfPublication69e40056-7a55-41b3-8a65-05aace0e07e3
relation.isAuthorOfPublication.latestForDiscovery69e40056-7a55-41b3-8a65-05aace0e07e3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus.pdf
Size:
2.19 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services